Xeligekimab is named as a drug or biological intervention in 3 clinical trials in our China trial register, 1 of which is recruiting. Lead sponsors include Chongqing Genrix Biopharmaceutical Co., Ltd (1), Lingli Dong (1) and First Hospital of China Medical University (1). Registered phases: Observational, Phase 2/3 and Phase 4. Conditions studied include Plaque Psoriasis; Psoriatic Arthritis; Scalp Psoriasis.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT07503652 | Clinical Observation of Xeligekimab in the Treatment of Moderate to Severe Palmoplantar Pustulosis (ClinicalTrials.gov ↗) Palmoplantar Pustulosis (PPP) |
Phase 4 | Recruiting |
| NCT07339566 | Efficacy and Safety of Xeligekimab in the Treatment of Non-Radiographic Axial Spondyloarthritis (ClinicalTrials.gov ↗) Nr-axial Spondyloarthritis, Non-Radiographical Axial Spondyloarthritis |
Phase 2/3 | Not yet open |
| NCT06802848 | Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real) (ClinicalTrials.gov ↗) Plaque Psoriasis, Psoriatic Arthritis, Scalp Psoriasis |
Observational | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Plaque Psoriasis | 1 |
| Psoriatic Arthritis | 1 |
| Scalp Psoriasis | 1 |
| Nail Psoriasis | 1 |
| Nr-axial Spondyloarthritis | 1 |
| Non-Radiographical Axial Spondyloarthritis | 1 |
| Palmoplantar Pustulosis (PPP) | 1 |
| Lead sponsor | Trials |
|---|---|
| Chongqing Genrix Biopharmaceutical Co., Ltd | 1 |
| Lingli Dong | 1 |
| First Hospital of China Medical University | 1 |
| Register | Xeligekimab trials |
|---|---|
| Clinical trials in China | 3 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Xeligekimab works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Xeligekimab (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.